Pre-stroke use of statins on stroke outcome: a meta-analysis of observational studies

Ann Cordenier*, Ann De Smedt, Raf Brouns, Maarten Uyttenboogaart, Sylvie De Raedt, Gert-Jan Luijckx, Jacques De Keyser

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    14 Citations (Scopus)

    Abstract

    Background: Animal pre-clinical studies suggest that statins may have neuroprotective effects in acute ischaemic stroke. Statins might also increase the risk of developing haemorrhagic transformation after thrombolytic treatment.

    Methods: We performed a systematic review and included studies that compared good functional outcome, defined as a modified Rankin Scale (mRS) score

    Results: Eleven studies met our predefined inclusion criteria. Statin therapy before stroke-onset was associated with a lower risk of in-hospital mortality (OR 0.56; 95% CI: 0.40 to 0.78, P <0.0006). There was no difference between the two groups for good functional outcome at 3 months (OR 1.01; 95% CI: 0.64 to 1.61, P = 0.96). Statin use was associated with an increased risk of developing symptomatic haemorrhagic transformation after thrombolytic therapy (OR 2.34; 95% CI 1.31 to 4.17, P = 0.004).

    Conclusions: Our meta-analysis suggests that pretreatment with statins does not improve 3 months functional outcome, defined as independence on mRS, but decreases in-hospital mortality and increases the risk of developing a symptomatic haemorrhagic transformation in patients treated with thrombolysis.

    Original languageEnglish
    Pages (from-to)261-267
    Number of pages7
    JournalActa neurologica belgica
    Volume111
    Issue number4
    Publication statusPublished - Dec-2011

    Keywords

    • Ischaemic stroke
    • statins
    • outcome
    • neuro-protection
    • thrombolysis
    • ICH
    • meta-analysis
    • ACUTE ISCHEMIC-STROKE
    • TISSUE-PLASMINOGEN ACTIVATOR
    • HEMORRHAGIC STROKE
    • NEUROPROTECTIVE PROPERTIES
    • MYOCARDIAL-INFARCTION
    • CHOLESTEROL LEVELS
    • PRETREATMENT
    • THROMBOLYSIS
    • PREVENTION
    • EVENTS

    Cite this